Clinical Trials Browser

Interventional × Anemia, Refractory × Decitabine × Clear all

NCT03358719 2026-02-27

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1 Completed

8 enrolled 9 charts

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01165996 2019-03-04

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Phase 1/2 Completed

25 enrolled 13 charts

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Thrombocytopenia, Leukemia, Myelomonocytic, Chronic

NCT00003361 2013-06-26

Decitabine in Treating Patients With Myelodysplastic Syndrome

Phase 2 Completed

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00043134 2010-04-13

Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome

Phase 3 Unknown

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative